ai3Bio
ai3Bio develops therapies designed to remove disease-causing Th17 immune cells, using antibody and lipid-nanoparticle platforms to address autoimmune disease.
$48MSeries A
ParticipantCI
Cockrell Interests
Activity from announced rounds
Activity in this selectionOct 16, 2026 · Sep 17, 2026
Cockrell Interests is the investment entity named in financing coverage for Stellular Bio and ai3Bio.
Recorded funding activity
Stellular develops platelet-derived biologic therapies for ocular-surface diseases. ai3Bio develops antibody and lipid-nanoparticle approaches intended to remove disease-causing Th17 immune cells. The company records connect the same named investor to distinct therapeutic programs.
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $48M 1 disclosed · full round size, not this investor’s share